Physician profile
Robert Leldon Sweet
NPI 1649249152
$1,387.42
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $563 · 2021: $394.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $428.36 | 2019-2021 | |
| Medtronic Vascular, INC. | $383.20 | 2019-2020 | |
| Amarin Pharma, INC. | $115.25 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $111.82 | 2019-2021 | |
| Medtronic, INC. | $84.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $64.56 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $45.27 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $33.98 | 2021 | |
| Esperion Therapeutics, INC. | $28.61 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $28.12 | 2020 | |
| Pfizer INC. | $14.58 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.42 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.99 | 2020 | |
| Gilead Sciences, INC. | $12.26 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sweet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.